06 November 2018
Unaudited Results for the nine months to 30 September 2018
Cambridge, UK and Indianapolis, US - 6 November 2018: Acacia Pharma Group plc ("Acacia Pharma", the "Company" or the "Group"), (EURONEXT: ACPH) announces its unaudited results for the nine months to 30 September 2018 to provide an update on current trading and its cash position.
As announced earlier today, the Group has resubmitted its New Drug Application for BARHEMSYS™ to the US Food and Drug Administration (FDA). FDA will classify the resubmission as either Class 1 or Class 2. The Group remains on track with its launch readiness plans and continues to expect to be ready to launch BARHEMSYS in H1 2019. Activities have been scheduled such that the Group can be launch-ready, with the timing of expenditure capable of being flexed to meet results of the decision around the FDA’s classification of the NDA resubmission.
Cash and cash equivalents as at 30 September 2018 were £33.8 million (30 June 2018: £35.7 million) slightly ahead of expectations at the time of the Company’s IPO in March 2018.
Acacia Pharma Group plc
Julian Gilbert, CEO
Christine Soden, CFO
+44 1223 919760
Dewe Rogerson, Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571
Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH. www.acaciapharma.com
Forward looking statements
This announcement includes forward-looking statements, which are based on current expectations and projections about future events. These statements may include, without limitation, any statements preceded by, followed by or including words such as "believe", "expect", "intend", "may", "plan", "will", "should", "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements may and often do differ materially from actual results. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and investments, including, among other things, the development of its business, trends in its operating industry, and future capital expenditures and acquisitions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's business, results of operations, financial position, prospectus, growth or strategies and the industry in which it operates. Save as required by law or applicable regulation, the Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. Forward-looking statements speak only as of the date they are made.